Calmodulin and Its Binding Proteins in Parkinson's Disease

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Apr 3

PMID 33809535

Citations 9

Authors

Anastasiia Bohush

Wieslawa Lesniak

Serge Weis

Anna Filipek

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder that manifests with rest tremor, muscle rigidity and movement disturbances. At the microscopic level it is characterized by formation of specific intraneuronal inclusions, called Lewy bodies (LBs), and by a progressive loss of dopaminergic neurons in the striatum and substantia nigra. All living cells, among them neurons, rely on Ca as a universal carrier of extracellular and intracellular signals that can initiate and control various cellular processes. Disturbances in Ca homeostasis and dysfunction of Ca signaling pathways may have serious consequences on cells and even result in cell death. Dopaminergic neurons are particularly sensitive to any changes in intracellular Ca level. The best known and studied Ca sensor in eukaryotic cells is calmodulin. Calmodulin binds Ca with high affinity and regulates the activity of a plethora of proteins. In the brain, calmodulin and its binding proteins play a crucial role in regulation of the activity of synaptic proteins and in the maintenance of neuronal plasticity. Thus, any changes in activity of these proteins might be linked to the development and progression of neurodegenerative disorders including PD. This review aims to summarize published results regarding the role of calmodulin and its binding proteins in pathology and pathogenesis of PD.

Citing Articles

Shared interactions of six neurotropic viruses with 38 human proteins: a computational and literature-based exploration of viral interactions and hijacking of human proteins in neuropsychiatric disorders.

Ozer E, Keskin A, Berrak Y, Cankara F, Can F, Gursoy-Ozdemir Y Discov Ment Health. 2025; 5(1):18.

PMID: 39987419 PMC: 11846830. DOI: 10.1007/s44192-025-00128-2.

The Search for a Universal Treatment for Defined and Mixed Pathology Neurodegenerative Diseases.

ODay D Int J Mol Sci. 2025; 25(24.

PMID: 39769187 PMC: 11678063. DOI: 10.3390/ijms252413424.

Assessing the predicted impact of single amino acid substitutions in calmodulin for CAGI6 challenges.

Turina P, Dal Cortivo G, Enriquez Sandoval C, Alexov E, Ascher D, Babbi G Hum Genet. 2024; .

PMID: 39714488 DOI: 10.1007/s00439-024-02720-y.

Loss of calcium/calmodulin-dependent protein kinase kinase 2, transferrin, and transferrin receptor proteins in the temporal cortex of Alzheimer's patients postmortem is associated with abnormal iron homeostasis: implications for patient survival.

Sabbir M Front Cell Dev Biol. 2024; 12:1469751.

PMID: 39669708 PMC: 11634808. DOI: 10.3389/fcell.2024.1469751.

The Complex Interplay between Toxic Hallmark Proteins, Calmodulin-Binding Proteins, Ion Channels, and Receptors Involved in Calcium Dyshomeostasis in Neurodegeneration.

ODay D Biomolecules. 2024; 14(2).

PMID: 38397410 PMC: 10886625. DOI: 10.3390/biom14020173.

References

Sharma R, Parameswaran S . Calmodulin-binding proteins: A journey of 40 years. Cell Calcium. 2018; 75:89-100. DOI: 10.1016/j.ceca.2018.09.002. View

Picconi B, Gardoni F, Centonze D, Mauceri D, Cenci M, Bernardi G . Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J Neurosci. 2004; 24(23):5283-91. PMC: 6729313. DOI: 10.1523/JNEUROSCI.1224-04.2004. View

Fedorenko O, Popugaeva E, Enomoto M, Stathopulos P, Ikura M, Bezprozvanny I . Intracellular calcium channels: inositol-1,4,5-trisphosphate receptors. Eur J Pharmacol. 2013; 739:39-48. PMC: 4040340. DOI: 10.1016/j.ejphar.2013.10.074. View

Chen X, Xue B, Wang J, Liu H, Shi L, Xie J . Potassium Channels: A Potential Therapeutic Target for Parkinson's Disease. Neurosci Bull. 2017; 34(2):341-348. PMC: 5856711. DOI: 10.1007/s12264-017-0177-3. View

Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

Selvaraj S, Sun Y, Watt J, Wang S, Lei S, Birnbaumer L . Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling. J Clin Invest. 2012; 122(4):1354-67. PMC: 3314472. DOI: 10.1172/JCI61332. View

. Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial. Ann Intern Med. 2020; 172(9):591-598. PMC: 7465126. DOI: 10.7326/M19-2534. View

Kuhn D, Sakowski S, Geddes T, Wilkerson C, Haycock J . Phosphorylation and activation of tryptophan hydroxylase 2: identification of serine-19 as the substrate site for calcium, calmodulin-dependent protein kinase II. J Neurochem. 2007; 103(4):1567-73. DOI: 10.1111/j.1471-4159.2007.04855.x. View

Chan C, Gertler T, Surmeier D . Calcium homeostasis, selective vulnerability and Parkinson's disease. Trends Neurosci. 2009; 32(5):249-56. PMC: 4831702. DOI: 10.1016/j.tins.2009.01.006. View

10.

Luo J, Sun L, Lin X, Liu G, Yu J, Parisiadou L . A calcineurin- and NFAT-dependent pathway is involved in α-synuclein-induced degeneration of midbrain dopaminergic neurons. Hum Mol Genet. 2014; 23(24):6567-74. PMC: 4240205. DOI: 10.1093/hmg/ddu377. View

11.

Creamer T . Calcineurin. Cell Commun Signal. 2020; 18(1):137. PMC: 7456046. DOI: 10.1186/s12964-020-00636-4. View

12.

Kumar A, Singh N . Calcineurin inhibitors improve memory loss and neuropathological changes in mouse model of dementia. Pharmacol Biochem Behav. 2017; 153:147-159. DOI: 10.1016/j.pbb.2016.12.018. View

13.

Shiba M, Bower J, Maraganore D, McDonnell S, Peterson B, Ahlskog J . Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord. 2000; 15(4):669-77. DOI: 10.1002/1531-8257(200007)15:4<669::aid-mds1011>3.0.co;2-5. View

14.

Jiang X, Mu D, Manabat C, Koshy A, Christen S, Tauber M . Differential vulnerability of immature murine neurons to oxygen-glucose deprivation. Exp Neurol. 2004; 190(1):224-32. DOI: 10.1016/j.expneurol.2004.07.010. View

15.

Bonifati V, Rizzu P, van Baren M, Schaap O, Breedveld G, Krieger E . Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2002; 299(5604):256-9. DOI: 10.1126/science.1077209. View

16.

Lee K, Huh S, Lee S, Wu Z, Kim A, Kang H . Altered ER-mitochondria contact impacts mitochondria calcium homeostasis and contributes to neurodegeneration in vivo in disease models. Proc Natl Acad Sci U S A. 2018; 115(38):E8844-E8853. PMC: 6156612. DOI: 10.1073/pnas.1721136115. View

17.

Shioda N, Fukunaga K . Physiological and Pathological Roles of CaMKII-PP1 Signaling in the Brain. Int J Mol Sci. 2017; 19(1). PMC: 5795971. DOI: 10.3390/ijms19010020. View

18.

Sompol P, Furman J, Pleiss M, Kraner S, Artiushin I, Batten S . Calcineurin/NFAT Signaling in Activated Astrocytes Drives Network Hyperexcitability in Aβ-Bearing Mice. J Neurosci. 2017; 37(25):6132-6148. PMC: 5481945. DOI: 10.1523/JNEUROSCI.0877-17.2017. View

19.

Mullins F, Park C, Dolmetsch R, Lewis R . STIM1 and calmodulin interact with Orai1 to induce Ca2+-dependent inactivation of CRAC channels. Proc Natl Acad Sci U S A. 2009; 106(36):15495-500. PMC: 2741279. DOI: 10.1073/pnas.0906781106. View

20.

Brini M, Cali T, Ottolini D, Carafoli E . Intracellular calcium homeostasis and signaling. Met Ions Life Sci. 2013; 12:119-68. DOI: 10.1007/978-94-007-5561-1_5. View